^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    OncoCompass™ Target

    Company:
    Burning Rock Biotech
    Type:
    CE Marked
    Related tests:
    Evidence Level:
    Sensitive: C3 – Early Trials

    [EGFR mutation-Lung Adenocarcinoma-gefitinib]

    Source:
    Lancet
    Test:

    OncoCompass™ Target

    Title:
    Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial
    Excerpt:
    426 patients were screened for the trial, of whom 188 with EGFR mutations in ctDNA were enrolled and received gefitinib...Median progression-free survival was 9·5 months (95% CI 9·07–11·04)...Detection of EGFR mutations in ctDNA is an effective method to identify patients who might benefit from first-line gefitinib treatment.
    DOI:
    10.1016/S2213-2600(18)30264-9
    Trial ID:
    NCT02282267